• Treatment of patients with chronic cyclical pelvic pain 
To content

Treatment of patients with chronic cyclical pelvic pain 

HEALTH OF WOMAN.2015.6(102): 71–74; doi 10.15574/HW.2015.102.71 
 

Treatment of patients with chronic cyclical pelvic pain 
 

Lakhno I. V.

Kharkiv medical Academy of postgraduate education 
 

Chronic pelvic pain (CPP) is one of the most common clinical syndromes that accompanies a number of gynecological diseases. The aim was to study the efficacy of treatment patients with cyclical CPP wit the application of herbal medications Vimens. It was examined 86 patients of reproductive age and 25 from them were apparently healthy and made up the group I. Group II was assigned 30 women with CPP who received COCs on an intermittent schedule and NSAID rectal suppositories for pain. In group III 31 patients with CPP assigned to single capsule Vimens daily and rectal NSAIDs in the presence of pain. It was studied the severity of the pain, the level of reactive and personal anxiety, and quality of life in all surveyed women. The work has suggesteda complex phytopreparation Vimens in patients with cyclical CPP pathogenetically substantiated. This was confirmed by a decrease in the amount of NSAIDs used in Group III at 3 months of treatment by 2.4 times compared to the group II. The appointment of Vimens additionally to NSAIDs has significantly reduced the level of pain on the VAS, reactive and personal anxiety in the test Spielberger-Khanin and quality of life with questionnaire SF-36. 
 

Key words: chronic pelvic pain, treatment, Vimens. 
 

REFERENCES

1. Bolca S, Li J, Nikolic D еt al. 2010. Dispositionofhopprenylflavonoids in human breast tissue. Mol Nutr Food Res. 54:284–294. http://dx.doi.org/10.1002/mnfr.200900519; PMid:20486208 PMCid:PMC3856213

2. Greiner T. 2011. Vitamins and minerals for women: recent programs and intervention trials. Nutr Res Pract. 5;1:3–10. http://dx.doi.org/10.4162/nrp.2011.5.1.3; PMid:21487490 PMCid:PMC3061267

3. Hajirahimkhan A, Simmler Ch, Yuan Y et al. 2013. Evaluation of Estrogenic Activity of Licorice Species in Comparison with Hops Used in Botanicals for Menopausal Symptoms. PLoS One 8;7:e67947.

4. Imanshahidi M, Hosseinzadeh H. 2006. The pharmacological effects of Salvia species on the central nervous system. Phytother Res. 20;6:427– 437. http://dx.doi.org/10.1002/ptr.1898; PMid:16619340

5. Kianbakht S, Abasi B, Perham M, Dabaghian HF. 2011. Antihyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double– blind placebo– controlled clinical trial. Phytother Res. 25;12:1849–1853. http://dx.doi.org/10.1002/ptr.3506; PMid:21506190

6. Kianbakht S, Dabaghian FH. 2013. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial. Complement Ther Med. 21;5:441–446. http://dx.doi.org/10.1016/j.ctim.2013.07.004; PMid:24050577

7. Koetter U, Biendl M. 2010. Hops (Humulus lupulus): A Review of its Historic and Medicinal Uses. HerbalGram. 87:44–57.

8. Krause E, Yuan Y, Hajirahimkhan A et al. 2014. Biological and chemical standardization of a hop (Humulus lupulus) botanical dietary supplement. Biomed Chromatogr. 28;6:729–734. http://dx.doi.org/10.1002/bmc.3177; PMid:24861737 PMCid:PMC4240625

9. Nevatte T, O’Brien PM, Backstrom T et al. 2013. ISPMD consensus on the management of premenstrual disorders. Arch WomensMent Health 16;4:279–291. http://dx.doi.org/10.1007/s00737-013-0346-y; PMid:23624686 PMCid:PMC3955202

10. Park SH, Sim YB, Kang YJ et al. 2012. Hop Extract Produces Antinociception by Acting on Opioid System in Mice. Korean J Physiol Pharmacol. 16;3:187–192. http://dx.doi.org/10.4196/kjpp.2012.16.3.187; PMid:22802700 PMCid:PMC3394921

11. Rani A, Sharma A. 2013. The genus Vitex: A review. Pharmacogn Rev. 7;14:188–198. http://dx.doi.org/10.4103/0973-7847.120522; PMid:24347927 PMCid:PMC3841997

12. Roelens F, Heldring N, Dhooge W et al. 2006. Subtle side–chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta. J Med Chem. 49:7357–7365. http://dx.doi.org/10.1021/jm060692n; PMid:17149865

13. Siedentopf F, Sillem M. 2014. Chronic pelvic pain in women. Schmerz. 28;3:300–304. http://dx.doi.org/10.1007/s00482-014-1408-4; PMid:24903044

14. Won H, Abbot J. 2010. Optimal management of chronic cyclical pelvic pain: an evidence-based and pragmatic approach. Int J Womens Health 2:263–277. PMid:21151732 PMCid:PMC2990894